Articles tagged with Cancer
Recent CAR-T cell modification strategies have enhanced recognition, immunity stimulation, killing activity, and safety. The new designs counteract tumor immune escape and immunosuppressive microenvironments.
Researchers at the University of Missouri have developed a new imaging probe that can help surgeons accurately identify and remove aggressive brain tumors during operations. The tool, known as FA-ICG, uses near-infrared light to highlight tumor cells from within.
Researchers at the University of Pennsylvania School of Engineering and Applied Science have turned a deadly fungus into a potent cancer-fighting compound. The new compound, called asperigimycins, has shown promising results against leukemia cells, rivaling FDA-approved drugs.
Researchers at UCL found that low-risk thyroid cancer patients can safely forego radioactive iodine treatment after surgery, allowing them to spend more time with family. This could impact hundreds of thousands of people worldwide, particularly younger parents and those living in the UK.
Cancer patients treated with immune checkpoint inhibitors are at risk of heart damage due to rapid loss of protective immune cells. Researchers found a biomarker, CD69, can predict which patients are most at risk and may help doctors monitor them more closely.
Scientists at Xi'an Jiaotong-Liverpool University developed a new nanoparticle capable of carrying high doses of chemotherapy drugs while staying stable for extended periods. This innovation could make treatments more effective and reduce side effects.
Researchers developed a tool to monitor treatment response in patients with solid tumours using circulating tumour DNA analysis, anticipating clinical relapses up to 68 months before symptoms become apparent. The technology is minimally invasive and can be tailored to each tumour type, reducing unnecessary treatments and costs.
The mitochondrial ribosomal protein family (MRPs) is dysregulated in various cancers, influencing tumor initiation and progression. MRPs regulate metabolic reprogramming of immune cells within the tumor microenvironment, affecting growth, migration, invasion, and chemoresistance.
The study highlights the importance of pro-inflammatory cytokines and CXC chemokines in tumor development and immune system modulation. Age-related changes in the tumor microenvironment, including extracellular matrix stiffening and inflammatory immune mediator accumulation, contribute to tumor growth, metastasis, and immune evasion.
Researchers at UT Health San Antonio have made a major discovery in understanding cancer drug resistance, specifically in BRCA1-deficient cancers treated with PARP inhibitors. The study reveals that problems in the CST complex can cause resistance to these drugs, opening doors to new therapies and personalized treatments.
Certain dietary patterns, such as high-salt foods and processed meats, create an environment conducive to GC development. Beneficial bacteria like Akkermansia muciniphila help protect against cancer by strengthening the immune response and maintaining healthy stomach conditions.
Boston College researchers create MapID-tRNA-seq, a method to map chemical modifications and expression of human transfer RNA. The study reveals that tRNA expressions are largely dysregulated in cancerous cells compared to benign cells.
The University of Texas Health Science Center at San Antonio is targeting hard-to-treat cancers and boosting HPV vaccination rates with a $3.4 million funding from CPRIT. The institution will expand its core facilities laboratories to increase researchers' ability to identify therapeutic targets and develop new cancer technologies.
Researchers found that combining selinexor with Irinotecan shrunk tumors in preclinical models of colorectal cancer, suggesting a new potential treatment. The study also identified XPO1 mutations linked to rare cancers like endometrial cancer and found that these mutations make cells resistant to chemotherapy.
Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.
Researchers at Osaka Metropolitan University discovered a new way to block cancer cell energy production by suppressing de novo fatty acid synthesis with ethyl p-methoxycinnamate. This natural substance inhibits ATP production, leading to increased glycolysis as a possible survival mechanism in tumor cells.
Dr. Stephen Ross's groundbreaking studies using psilocybin therapy have demonstrated rapid, substantial, and sustained improvements in psychological symptoms for patients with advanced cancer, substance use disorders, and major depressive disorder. His research has the potential to challenge conventional psychiatric medication approaches.
Experts from the National Comprehensive Cancer Network (NCCN) and African Cancer Coalition gathered in Nairobi, Kenya to update NCCN Clinical Practice Guidelines in Oncology for Sub-Saharan Africa. The meeting aimed to improve cancer care in the region by sharing evidence-based recommendations.
Researchers at the University of Mississippi have discovered a sea cucumber sugar compound that effectively blocks Sulf-2, an enzyme crucial for cancer growth. The compound may be easier to create and safer to use than traditional medications, with potential benefits for natural cancer therapy.
A study on long-lived bats found that they possess robust tumor-suppressor mechanisms that protect against cancer. The researchers discovered that increased activity of the p53 gene is a key defense against cancer, and that safely increasing telomerase enzyme activity could be a way to apply their findings to humans.
The Open Access Team, led by Sergei Kurenov, rides to support cancer research and honor Dr. Mikhail Blagosklonny's legacy through open-access publishing. Impact Journals is sponsoring the team in this year's Ride for Roswell event.
A new study explains how the gene CDK12 drives high-grade serous tubo-ovarian carcinoma, a rare and aggressive form of ovarian cancer. Researchers discovered that inactivating CDK12 triggers an immune cell response and identified a partner gene, CDK13, as a target for a degrader or inhibitor.
A new study of 591 women with early-stage breast cancer found that nearly two-thirds opted for continued endocrine therapy beyond the initial five years. Patients with higher-risk stage 2 disease were more likely to continue treatment, highlighting potential benefits in extending hormone-based therapy for these patients.
Researchers found that using Tumor Treating Fields therapy (TTFields) combined with immunotherapy (pembrolizumab) and chemotherapy (temozolomide) may extend survival for glioblastoma patients. TTFields disrupt tumor growth, attracting more immune cells to attack cancerous cells.
The Canadian Indigenous Nurses Association and the Ontario Institute for Cancer Research are partnering to improve cancer research with Indigenous communities. The partnership aims to address unique cancer-related priorities of First Nations, Inuit, and Métis populations by supporting training and advancement of Indigenous researchers....
A state Medigap guaranteed issue protection was associated with a higher rate of switching to traditional Medicare among newly diagnosed cancer patients. This finding suggests that these regulations can facilitate a switch, especially for those who desire more flexibility in accessing care.
A real-world study found that mailed self-collection HPV tests significantly increased cervical cancer screening participation among never- and under-screened US women. Women who received the self-collection kits were more than twice as likely to participate in screening compared to those who received only a telephone reminder.
A Chinese Medical Journal study investigates the role of non-coding RNAs in pancreatic cancer, revealing how dysregulation of these molecules contributes to tumor growth and treatment resistance. The research highlights potential therapeutic targets for this devastating disease.
Researchers found that CBR3-AS1 and PCA3 were significantly overexpressed in gastric cancer tissues, suggesting their involvement in GC development. The study supports the use of these lncRNAs as diagnostic biomarkers.
Recent advances in tissue-agnostic cancer drugs have resulted in highly effective treatments, but few are approved for children. Oncologists argue that these drugs should be licensed for all ages due to their effectiveness and fewer side effects. The researchers suggest that age-agnostic approvals could be made through analyzing electr...
Researchers found that higher McCance Brain Care Score is associated with lower risk of cardiovascular disease and three common cancers worldwide. The score evaluates physical, lifestyle, and social-emotional domains linked to brain health.
A cohort study found that obesity in childhood cancer survivors is linked to an increased risk of developing multiple subsequent neoplasms. Conversely, high levels of physical activity are associated with a reduced risk of these cancers.
A revolutionary AI model has been developed to diagnose lung cancer without relying on costly GPU servers or massive datasets. The ultra-lightweight model achieved a discrimination performance corresponding to an AUC value of 0.92, outperforming state-of-the-art large-scale AI systems.
The ESMO Gynaecological Cancers Congress 2025 will convene in Vienna, Austria, from June 19-21, featuring novel data on immunotherapy combinations and emerging treatment strategies for rare gynaecological cancers. The congress will also explore innovative approaches using antibody-drug conjugates.
Researchers developed self-propelled ferroptosis nanoinducers to enhance cancer therapy by inducing programmed cell death. The nanotherapeutics exhibited enhanced diffusion and deep tumor penetration while maintaining biocompatibility.
Researchers developed a patient-derived organoid library to study chemotherapy resistance in esophageal cancer. Lab-grown mini-tumors showed increased activity in the NRF2 pathway, suggesting potential biomarkers for predicting chemotherapy resistance.
Researchers detected genetic material from tumors in the bloodstream three years before cancer diagnosis. This early detection provides time for intervention and potentially more curable treatments.
Researchers at Ben-Gurion University of the Negev have made a breakthrough in harnessing patient's own T-cells to fight off cancer by creating artificial surfaces mimicking natural immune cells. These surfaces, engineered with nanostructures, strengthen and prolong activation of T-cells, leading to more effective immunotherapy.
Researchers identified a link between the loss of Y chromosome in white blood cells and reduced ability to kill cancer cells. This finding may explain why men with loss of Y have higher cancer risks and poorer outcomes. The study provides insights into how this genetic change affects immune system function.
A new study uses preserved plants and animals from natural history museums to track pollution trends over two centuries. Researchers found significant changes in pollutant levels between specimens collected in the 19th and 20th centuries, highlighting the impact of industrial activity on human health.
A University of British Columbia-led study found that colorectal cancer survivors experience a range of long-term sexual health issues, including dyspareunia and pelvic inflammatory disease. The study highlights the need for better education and support for women after cancer.
A Rice University-led research team is working on a new approach to treat acute myeloid leukemia (AML) by targeting the energy-producing mitochondria of cancer cells. By disrupting mitochondrial function, the researchers aim to selectively kill AML cells while leaving healthy blood cells unharmed.
A team at IRB Barcelona developed a tool to generate customized aneuploidies, precisely labeling cells carrying these abnormalities in living tissue. This allows for real-time observation of cell behavior, revealing the presence of haploinsufficient genes and their removal through cell competition.
Dr. Nikolaos Koundouros has been awarded the 2025 Tri-Institutional Breakout Award for his research on how cells detect and respond to dietary nutrients, specifically omega-6 and omega-3 fatty acids, in relation to breast cancer development.
A five-year analysis of the CheckMate-816 clinical trial shows that immunotherapy plus chemotherapy before lung cancer surgery significantly improves long-term survival. Patients who achieved complete remission had a 95% five-year survival rate.
Researchers discovered that blocking PRDX1 protein can make ovarian cancer cells more responsive to DNA-damaging platinum therapies. The study suggests targeting PRDX1 could be a viable strategy to improve chemotherapy efficacy.
Researchers identified the PROX1 gene as an early driver of prostate cancer aggression, which leads to treatment-resistant tumors. The team found that a class of FDA-approved drugs, HDAC inhibitors, can disable PROX1 and reduce tumor survival in aggressive prostate cancer subtypes.
A global clinical trial led by Irish cancer specialist Prof. Patrick Forde shows that immunotherapy with chemotherapy before lung cancer surgery reduces the risk of cancer returning and improves long-term survival. The study found that patients who received immunotherapy plus chemotherapy had improved outcomes compared to those who rec...
A new study from Fox Chase Cancer Center researchers found that implementing a Best Practice Advisory in the electronic medical record system increased oncofertility referrals by 450%. This led to 14 successful fertility preservation cases within six months, compared to just 22 in the previous five years.
A high-fiber plant-based diet improved health markers that could delay the progression of precancerous conditions and multiple myeloma. The study showed significant improvements in dietary quality, weight loss, metabolic markers, inflammation, and gut microbiome diversity.
Researchers used canine DNA to identify over 15 genes linked to gastric cancer in humans, offering promising new avenues for research. The study suggests genetic testing could help diagnose the disease earlier and guide breeding decisions to reduce disease prevalence.
Rapid advances in cancer treatment have improved long-term survival rates, but current resources and models of care in Canada do not meet the changing needs of people with cancer. The authors propose solutions such as reducing unnecessary surveillance and establishing interdisciplinary specialty clinics.
Combining immunotherapy drug dostarlimab with standard chemotherapy improved survival and reduced symptoms in patients with advanced endometrial cancer. Patients lived up to 5.5 months longer with fewer side effects, outweighing risks.
A recent randomized controlled trial found that a group-based intervention fostering communication and coping skills in a culturally tailored way improved outcomes for Latina breast cancer survivors and their caregivers. The study, published in CANCER journal, demonstrated high engagement among participants and clinically significant i...
Charité researchers identified a therapeutic target that significantly contributes to halting ongoing inflammatory processes. They found that interleukin-22 and oncostatin M drive inflammation by amplifying the immune response. Targeted treatments may help high-risk patients, but chronic diseases remain complex and difficult to predict.
The ASCENT-04/KEYNOTE-D19 study shows that sacituzumab govitecan plus pembrolizumab improves progression-free survival and response rates compared to chemotherapy. Nearly 60% of patients responded, with durable responses lasting up to 16.6 months.
A phase 2 trial found that combining avelumab and cetuximab significantly extended median progression-free survival in patients with advanced cutaneous squamous cell carcinoma. The combination showed synergistic effects, suggesting a potential new standard of care for this patient population.
A new app, BMT-CARE App, was tested in a randomized clinical trial to help caregivers manage stress and emotions related to bone marrow transplant patients. The app showed significant improvements in quality of life, burden, and mood symptoms compared to standard services.
The American Cancer Society estimates that 18.6 million people in the US live with a history of cancer as of January 1, 2025, and this number is projected to increase to over 22 million by 2035. The study highlights notable disparities in treatment for common cancers, including lung and colorectal cancer.
DB-1310, a HER3-targeted antibody-drug conjugate, has shown real potential as a new treatment option for patients with advanced solid tumors that have progressed after standard therapies. In an international clinical trial, DB-1310 demonstrated significant tumor shrinkage and delayed cancer growth in 44% of EGFR-mutant NSCLC patients.